New Software Tool Aids Early Diagnosis of Parkinson’s Disease Psychosis

New Software Tool Aids Early Diagnosis of Parkinson’s Disease Psychosis
3.7
(3)

PointClickCare has developed a new software tool to aid in the early diagnosis of Parkinson’s disease psychosis.

The tool, developed in partnership with the American Society of Consultant Pharmacists (ASCP), is programmed to ask patients a series of questions regarding hallucinations and/or delusions. Based on the responses, senior care providers may then engage in a conversation to collect more information and to design a care plan to manage the symptoms associated with Parkinson’s disease psychosis.

The Parkinson’s psychosis screener is available to all who wish to take part in PointClickCare’s free clinical content offer. More information is available here.

“Not only will the screener tool better enable faster diagnosis, it will provide the senior care industry with a consistent way of approaching Parkinson’s Psychosis,” Bill Stuart, clinical product strategist at PointClickCare, said in a press release.

“At PointClickCare, we understand the industry needs a standard approach to care by delivering standardized content that ultimately leads to standard data. Standard data is the only way to look across facilities to identify trends that can potentially provide new workflows and/or lead to new treatments,” he said.

Parkinson’s disease psychosis, a non-motor symptom of Parkinson’s, is often misdiagnosed.

Psychosis is the term used when Parkinson’s patients experience hallucinations and delusions. While hallucinations are more likely to occur in the later stages of Parkinson’s disease, younger and newly diagnosed patients also may experience them.

Manifestations of psychosis often appear at night when caregivers are unaware of such symptoms. As a result, patients often are prescribed antipsychotic medications that are not adequate, with the underlying cause of their symptoms remaining undiagnosed.

Besides aiding in the early diagnosis of psychosis among older patients, the data collected via the Parkinson’s psychosis screener will be integrated in PointClickCare’s Lighthouse initiative, a platform where data is shared to boost scientific research on Parkinson’s psychosis, among other topics.

“Parkinson’s Psychosis impacts many older people worldwide, and we’re thrilled to play a role in enabling earlier detection so that patients can receive the treatment they need sooner,” said Chad Worz, board certified geriatric pharmacist, and chief executive of ASCP.

“We are excited to have another tool for care teams to facilitate a more standardized care process for Parkinson’s Disease and we are excited for the role that pharmacists play in this process,” Worz said.

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 208
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • Psychosis
  • Nuplazid review
  • CST-2032, first participants dosed
  • deep brain stimulation

How useful was this post?

Click on a star to rate it!

Average rating 3.7 / 5. Vote count: 3

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?